echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Is the second batch coming? Expansion, increment, linkage 8 big cities and 42 drugs are expected to be selected

    Is the second batch coming? Expansion, increment, linkage 8 big cities and 42 drugs are expected to be selected

    • Last Update: 2019-04-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Some days ago, the executive meeting of the State Council stressed that we should further promote the national drug centralized procurement pilot, carefully summarize the pilot experience, and promote it in a timely and comprehensive manner This means that in the next round of national volume procurement, the pilot area is likely to expand, and the varieties involved are likely to increase With the expansion of the pilot area and the active participation of non pilot cities, the national linkage of bid winning price is expected to accelerate, and the national promotion of volume procurement mode is just around the corner With the gradual expansion of the influence of national volume procurement, domestic and foreign pharmaceutical enterprises frequently act Xie Bing, chairman of China's biopharmaceutical board of directors, said recently that the second batch of "4 + 7" with volume procurement varieties is expected to be announced this summer and implemented at the end of this year According to the prediction of mienei.com, if the pilot area is to be expanded, 8 cities are more likely to be shortlisted, and if the variety is to be increased, 42 drugs are more likely to be shortlisted Expansion, increment On April 3, the executive meeting of the State Council heard reports on centralized drug procurement, short supply of drugs and medical assistance, asking more people to benefit from drug use and medical treatment In terms of centralized drug procurement, the meeting stressed the need to further promote the national drug centralized procurement pilot, strengthen the quality supervision and supply guarantee of winning drugs, and realize price reduction for the benefit of the people; earnestly summarize the pilot experience, and timely and comprehensively push forward This means that in the next round of national volume procurement, the pilot area is likely to expand, and the varieties involved are likely to increase Expand the region At present, China has 4 municipalities directly under the central government, 15 sub provincial cities (Shenzhen, Dalian, Qingdao, Xiamen and Ningbo are separately listed in the plan) The first batch of "4 + 7" pilot cities for volume procurement include 4 municipalities directly under the central government (Beijing, Shanghai, Tianjin and Chongqing) and 7 sub provincial cities (Guangzhou, Shenzhen, Shenyang, Dalian, Xi'an, Chengdu and Xiamen) These cities can be more flexible or even independent To raise local financial resources, the finance is more abundant than other places, and the cooperation degree of local government and its functional departments is higher Figure 1: Chemical Terminal City pattern of public hospitals in key cities in 2018 (unit: RMB 100 million) (source: competition pattern of chemical terminal of public hospitals in key cities of mienei.com) In addition, according to the intranet database, Beijing, Shanghai and Guangzhou in the 4 + 7 cities ranked in the top three in the public hospital chemical terminal city pattern in 2018, with sales exceeding 10 billion yuan, and sales in Chengdu, Tianjin, Chongqing and other cities were also relatively good Therefore, if we want to expand the pilot area, we should choose the sub provincial cities with the above characteristics Hangzhou, Ningbo, Wuhan, Nanjing, Jinan, Harbin, Qingdao and Changchun have a great chance to be selected In 2018, Hangzhou and Wuhan ranked fifth and sixth in the chemical terminal city pattern of public hospitals in key cities, and Wuhan has launched GPO last year, which is similar to Guangzhou and Shenzhen, while Hangzhou and Ningbo belong to Zhejiang Province, which has well combined provincial bidding procurement and medical insurance payment standards, and Qingdao has its own characteristics in the major disease relief system In the first batch of "4 + 7" volume procurement of increased varieties, 31 varieties were shortlisted, and 25 varieties were finally selected Through analysis of 31 shortlisted varieties, it can be found that the original drugs, drugs with consistency evaluation and reference preparations are qualified to participate in the campaign, that is, the quality of drugs must be guaranteed; the shortlisted drugs are widely used in clinical practice and the amount of drugs is relatively large; The shortlisted varieties are mainly in cardiovascular system and nervous system, and the number of other fields is relatively small It is expected that the next batch will add more varieties in anti-tumor, diabetes and antibiotics The products approved and listed overseas are also likely to be shortlisted For example, some products of Huahai Pharmaceutical Co., Ltd and Shiyao group have been evaluated exclusively, and the amount of medication is not particularly large According to the statistics of minenet, as of April 10, 249 acceptance numbers have passed or deemed to have passed the consistency evaluation, involving 120 varieties (calculated by drug name) According to the above selection characteristics, 42 varieties (calculated by the way of Drug Administration) are selected by the minenet, which are expected to be included in the second batch of national volume purchase list Table 1: varieties that may be included in the second batch of volume purchase note: those with * are the first batch of volume purchase flow standard varieties (source: minenet database, data statistics as of April 10) From the perspective of sales volume and competition pattern, 22 of the 42 varieties had a terminal sales volume of more than 1 billion yuan in China's public medical institutions in 2017 Nearly half of the varieties were dominated by the original research manufacturers in the domestic market There is a large space for generic pharmaceutical enterprises to replace the original research In the first batch of belt quantity procurement, the injection that has passed or deemed to pass the consistency evaluation by the enterprise has appeared in the circulating list, but in the official documents, there is no "figure" of paclitaxel for injection (albumin binding type) and cefazolin sodium for injection / sodium chloride injection, while azithromycin for injection has not been finally selected due to price reasons, which is expected to be in the second batch of belt quantity procurement, Temozolomide for injection, ibuprofen injection, docetaxel injection and azithromycin for injection are all likely to be shortlisted Desflurane of Hengrui, cefadroxil and tramadol of euryi pharmaceutical, nevirapine of Huahai, ondansetron of Qilu, etc have been approved for listing abroad Although the sales volume of China's public medical institutions in 2017 is not very high, they are also likely to be shortlisted With the pilot cities as the fulcrum, price linkage and national promotion are the general trend for volume procurement At the executive meeting of the State Council on April 3, it was also stressed that "we should carefully summarize the pilot experience and push it out in a timely and comprehensive manner", which means that in addition to the possible expansion of the pilot areas and the possible increase of the varieties involved, the price linkage is expected to speed up, and the volume procurement mode is expected to be promoted nationwide Recently, the event that the price difference of "4 + 7" selected varieties in pilot cities and non pilot cities is more than ten times has been widely spread in the pharmaceutical industry Moreover, under the active role of some production enterprises, the outside market even has the situation that the price of the winning products does not fall but rises instead, and the collusion may become the "loophole" in the implementation of "4 + 7" volume procurement For manufacturers, the flow of low-priced drugs to high-priced areas will lead to confusion in their channel price system Therefore, some selected varieties of manufacturers are negotiating or have implemented the national market price linkage sales strategy For example, youmeituomidine hydrochloride injection of Yangtze River Pharmaceutical Co., Ltd has been priced in non "4 + 7" pilot cities such as Zhejiang, Liaoning, Shandong, Gansu and Shaanxi; For the medical insurance department, the drug prices in non pilot cities are higher than those in pilot cities, which will lead to the over expenditure of medical insurance expenses in the city So it seems that the price national linkage is the general trend On April 8, Liaoning Province issued a notice that 14 cities in the province formed a joint bargaining group for centralized purchase of drugs, which is responsible for the joint bargaining work of centralized purchase of drugs for medical institutions in the province Although it is difficult to judge whether it is related to volume purchase according to the documents, it is bound to contain some impulse of "price discovery" Previously, Liaoning Province has clearly stated that, in addition to Shenyang and Dalian, it is in the process of meeting the demand Under the premise of medical insurance payment policy and drug payment settlement, encourage the participation of the city as a unit in the pilot; as early as before the "4 + 7" was officially implemented, Fujian Province had made it clear that the province should follow up the results of volume purchase; Guangdong Province also issued a notice in March, requiring that the principle of centralized volume purchase should be adhered to, and the third-party drug electronic trading platform of Guangdong Province and GPO platforms of Guangzhou and Shenzhen should be promoted to implement price linkage as a whole; In addition, according to industry news, Sichuan also intends to follow up with the volume of procurement It can be seen that although only municipalities directly under the central government and sub provincial cities participate in the pilot of volume procurement, more and more provinces have taken the pilot cities as the fulcrum to respond positively to volume procurement With the expansion of pilot cities and more provincial-level follow-up, it is only a matter of time before the national linkage of bid winning prices and the national promotion of procurement mode with volume From cities to provinces and then to the whole country, with the national linkage of bid price and the national promotion of volume purchase mode, the above phenomenon of different prices of the same drug may be solved A new round of price "critical strike" is coming, and the frequent actions of multinational pharmaceutical enterprises have gradually expanded the influence of "4 + 7" volume procurement: the State Council has made it clear that further promoting volume procurement, the pilot area is expected to expand, the number of participating varieties is expected to increase, and the scope of influence is expected to increase; Recently, Xi'an, one of the "4 + 7" pilot cities, issued a notice to implement the "4 + 7" pilot monitoring task, and proposed to use the "4 + 7" selected varieties to replace other similar varieties; the first batch of "4 + 7" met the expectation in the implementation, even exceeded the expectation, pharmaceutical companies participated in the second batch of high enthusiasm for volume procurement, and the game in price will be more intense Under the volume purchase, the first job to be affected is the pharmaceutical representative According to the economic observer, since the first batch of volume purchase drugs list was published in December 2018, at least 40% of pharmaceutical representatives in the pharmaceutical industry have left voluntarily or forced With the nationwide promotion of the volume purchase mode, more and more drugs participate in it, and more and more pharmaceutical representatives will leave In addition, multinational enterprises are also frequent—— One is to constantly adjust its own structure For example, Sanofi has merged "4 + 7" Plavix and ambove into the same product pipeline, Kesai and novele have also been merged, and Pfizer, a cosmos pharmaceutical company, has also independent its newly established mature product business division from the company, which belongs to Pfizer puqiang It is reported that Pfizer puqiang contains many drugs that have passed the patent period Second, the price of imatinib mesylate tablets has been applied for in Shaanxi, Gansu, Yunnan, Zhejiang, Guizhou and other cities; Pfizer's atorvastatin calcium and amlodipine besylate, Xi'an YANGSEN's risperidone and escitalopram oxalate have been reduced to different degrees in Sichuan; Li Lai's olanzapine orally disintegrating tablets and pemetrexed disodium dropped prices in Liaoning and Zhejiang respectively Source: minenet database, economic observer, etc
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.